Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03655002
Other study ID # 18245
Secondary ID NCI-2018-0178618
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date February 21, 2019
Est. completion date December 15, 2024

Study information

Verified date January 2024
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase Ib trial studies the side effects and best dose of IRX-2 when given together with cyclophosphamide and nivolumab in treating patients with liver cancer that has come back or spread to other parts of the body and does not response to treatment. Biological therapies, such as IRX-2, may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IRX-2, cyclophosphamide, and nivolumab may work better than the IRX?2 regimen alone in treating patients with hepatocellular carcinoma.


Description:

PRIMARY OBJECTIVES: I. To determine the safety profile of combination IRX?2 regimen and nivolumab in anti?PD?1/PD?L1 naive patients who have failed or not tolerated at least one line of treatment. SECONDARY OBJECTIVES: I. To evaluate the overall response rate of IRX?2 regimen combined with nivolumab using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune modified RECIST criteria. II. To evaluate the rate of 6?month progression?free survival in patients treated with combination IRX?2 regimen with nivolumab. III. To evaluate median progression?free survival and overall survival. EXPLORATORY OBJECTIVES: I. To evaluate the circulating T cell profiles in patients before and after therapy with the combination IRX?2 regimen and nivolumab. II. To explore identification of tumor tissue neoantigens through a multiplex proteomic assay (MHC?PepSeq) paired with tumor genomic and transcriptomic sequencing. III. To explore putative biomarkers (including circulating tumor deoxyribonucleic acid [DNA] and immune cell profiles) in peripheral blood to generate hypotheses for response to treatment with combination IRX?2 regimen and nivolumab. OUTLINE: This is a dose-escalation study of IRX-2. Patients receive nivolumab intravenously (IV) over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 subcutaneously (SC) for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months. After completion of study treatment, patients are followed up every 12 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 8
Est. completion date December 15, 2024
Est. primary completion date December 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with histologically or cytologically confirmed recurrent or metastatic hepatocellular carcinoma (HCC). - Patients must have recurrent or metastatic HCC that are not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy). - Must have failed or not tolerated at least one line of treatment for advanced HCC. - Willing and able to give informed consent and adhere to protocol therapy; written informed consent and any locally required authorization must be obtained from the patient prior to performing any protocol?related procedures, including screening evaluations. - Up to three prior systemic therapy regimens for recurrent and/or metastatic disease. - Eastern Cooperative Oncology Group (ECOG) 0?1. - Have a Child?Pugh class A liver score within 7 days of first dose of study drug. - Hemoglobin > 8 g/dL. - Absolute neutrophil count (ANC) > 1,200 x 10^9/mL. - Platelet count > 60 x 10^9/mL. - Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). - Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT/serum glutamate pyruvate transaminase [SGPT]) =< 5 x ULN. - Serum albumin > 3.0 g/dL. - Prothrombin time (PT) and partial thromboplastin time (PTT) < 1.5 x the ULN. - Measured creatinine clearance (CL) > 40 mL/min or calculated creatinine clearance CL > 40 mL/min by the Cockcroft?Gault formula 10 or by 24?hour urine collection for determination of creatinine clearance. - Palliative radiation therapy is allowed to non?target lesions at the discretion of the treating physician. - Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as outlined in RECIST version 1.1. - Life expectancy of greater than 3 months. - Subjects with chronic infection by hepatitis C virus (HCV) who are untreated are allowed on study. In addition, subjects with successful HCV treatment (defined as sustained virologic response [SVR] 12 or SVR 24) are allowed as long as 4 weeks have passed between completion of HCV therapy and start of study drug. - Subjects with hepatitis B virus (HBV) may only be enrolled if their hepatitis is judged clinically stable by the investigator. - Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment. - Body weight > 30 Kg. Exclusion Criteria: - Prior exposure to PD?1/PD?L1 inhibitors. - Prior exposure to IRX?2 regimen. - Radiation therapy with a curable intent within 30 days of first dose of study treatment is excluded. However, radiation therapy with a palliative intent is allowed as long as treatment with study medication occurs >= 14 days after last dose of radiation and as long as there is at least 1 evaluable non?treated target lesion remaining. - Any medical contraindications or previous therapy that would preclude treatment with the IRX 2 regimen or nivolumab including the following: - Patients with allergies to ciprofloxacin or phytohemagglutinin (PHA). - Patients with evidence of pre?existing myelosuppression, myelodysplasia or hemorrhagic cystitis. - Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. - Patients with grade >= 2 neuropathy will be evaluated on a case?by?case basis after consultation with the study physician. - Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with IRX?2, nivolumab may be included only after consultation with the study physician. - Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: - Patients with vitiligo or alopecia. - Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement. Any chronic skin condition that does not require systemic therapy. - Patients without active disease in the last 2 years may be included but only after consultation with the study physician. - Patients with celiac disease controlled by diet alone. - Current or prior use of immunosuppressive medication within 14 days before the first dose of nivolumab. The following are exceptions to this criterion: - Intranasal, inhaled, topical steroid or local steroid injections (e.g., intra articular injection). - Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent. - Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication). - Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of nivolumab. - Note: Local surgery of isolated lesions for palliative intent is acceptable. - History of allogenic organ transplantation. - Symptomatic cardiopulmonary disease (including congestive heart failure and hypertension), coronary artery disease, serious arrhythmia or chronic lung disease. Patients with these conditions who are stable with relatively minor symptoms and who are appropriate candidates for systemic treatments need not be excluded. - Myocardial infarction within the last 3 months. - Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). - Has untreated active Hepatitis B. - Note: To qualify for enrollment, antiviral therapy for HBV must be given for at least 3 months, and HBV viral load must be less than 100 IU/mL prior to first dose of study drug. Those on active HBV therapy with viral loads under 100 IU/mL should stay on the same therapy throughout trial treatment. Those subjects who are anti?HBc (+), and negative for hepatitis B surface antigen (HBsAg), and negative for anti? HBs, and have an HBV viral load under 100 IU/mL do not require HBV anti?viral prophylaxis, but need close monitoring. - Has dual infection with HBV/HCV or other hepatitis combinations at study entry. - Receipt of live attenuated vaccine within 4 months prior to the first dose of study treatment. - Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 4 months after the last dose of study treatment. Inactivated vaccines should not be administered within 2 weeks prior to or after study regimen (ideally 4 weeks). - Signs or symptoms of systemic infection (use of antibiotics to treat superficial infection or contamination of tumor shall not, by itself, be considered evidence of infection). - Stroke or other symptoms of cerebral vascular insufficiency within the last 3 months. - Previous diagnosis of invasive cancer from which the individual is not disease?free AND that has required treatment within the past 3 years, except for superficial skin, cervical cancer in?situ, or early stage prostate or bladder cancer (i.e. treatment with curative intent and long term disease?free expectations). - History of leptomeningeal carcinomatosis. - Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. - Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to one year after last dose of cyclophosphamide or 180 days after the last dose of nivolumab therapy, whichever is longer.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclophosphamide
Given IV
Biological:
Cytokine-based Biologic Agent IRX-2
Given SC
Nivolumab
Given IV

Locations

Country Name City State
United States Texas Oncology at Baylor Charles A Sammons Cancer Center Dallas Texas
United States City of Hope Medical Center Duarte California
United States HonorHealth Research Institute Scottsdale Arizona

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Circulation T cell profiles Up to 2 years
Other Tumor neoantigen Using multiplex proteomic assay. Up to 2 years
Other Circulating immune cell profiles circulating tumor deoxyribonucleic acid (DNA) From peripheral blood. Up to 2 years
Primary Recommended phase II dose This is based on Simon?s MiniMax design. Up to 28 days
Primary Incidence of adverse events Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0. Up to 2 years
Secondary Overall response rate Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Best response and the percentage of participants with a best response of partial response or better will be summarized. Up to 2 years
Secondary Median progression-free survival (PFS) Per RECIST 1.1. PFS will be summarized using Kaplan?Meier methods. Time between study enrollment and when objective evidence of disease progression is documented, assessed up to 2 years
Secondary PFS PFS rate will be summarized using Kaplan?Meier methods. At 6 months
Secondary Overall survival Time between study enrollment and death, assessed up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Completed NCT02728219 - Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion N/A
Active, not recruiting NCT02867592 - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase 2
Active, not recruiting NCT04677088 - TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT03609268 - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma N/A
Completed NCT02613156 - Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma N/A
Recruiting NCT02719782 - A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation Phase 1
Recruiting NCT04800497 - The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC
Active, not recruiting NCT03257761 - Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Phase 1
Terminated NCT02762266 - Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization Phase 3
Withdrawn NCT01318200 - Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Phase 3
Completed NCT01015833 - Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 3
Recruiting NCT04663035 - Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Phase 2
Withdrawn NCT05327738 - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04615143 - Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC Phase 2
Active, not recruiting NCT04805788 - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Phase 2
Withdrawn NCT03634683 - A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation Phase 1/Phase 2